Thioridazine Interferences with Imipramine Metabolism and Measurement
- 1 December 1996
- journal article
- case report
- Published by Wolters Kluwer Health in Therapeutic Drug Monitoring
- Vol. 18 (6) , 729-731
- https://doi.org/10.1097/00007691-199612000-00018
Abstract
A case is presented in which toxic concentrations of imipramine (Tofranil) resulted from the co-administration of low-dose thioridazine (Mellaril). This probably occurred in an individual with genetically reduced capacity for oxidative drug metabolism, specifically via thioridazine's interference with the hepatic cytochrome P450IID6 isoenzyme (CYP2D6). In addition, coelution of thioridazine and its metabolites resulted in false elevations of imipramine and desipramine as measured by a common high-performance liquid chromatography (HPLC) method (cyanopropyl column). In contrast, an enzyme immunoassay (Abbott TDxFLx) and a second reference HPLC method (silica column) accurately resolved the analytes. This combination of psychiatric drugs is not uncommon in the pediatric population and is one of which both clinicians and laboratorians need to be aware. To the author's knowledge, this is the first report of interferences of thioridazine with both the metabolism and measurement of imipramine in a pediatric patient.Keywords
This publication has 4 references indexed in Scilit:
- Debrisoquin and mephenytoin hydroxylation phenotypes and CYP2D6 genotype in patients treated with neuroleptic and antidepressant agentsClinical Pharmacology & Therapeutics, 1993
- Immunoassay Reagents for Psychoactive Drugs. Part 3. Removal of Phenothiazine Interferences in the Quantification of Tricyclic AntidepressantsTherapeutic Drug Monitoring, 1993
- Application of a diode‐array detector in capillary electrophoresisElectrophoresis, 1993
- Debrisoquine oxidation phenotype during neuroleptic monotherapyEuropean Journal of Clinical Pharmacology, 1991